JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients harboring TRK fusion proteins. However, acquired resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jie, Zhou, Yang, Tang, Xia, Yu, Xiuwen, Wang, Yongjin, Chan, Shingpan, Song, Xiaojuan, Tu, Zhengchao, Zhang, Zhimin, Lu, Xiaoyun, Zhang, Zhang, Ding, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570838/
https://www.ncbi.nlm.nih.gov/pubmed/36235036
http://dx.doi.org/10.3390/molecules27196500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570838/
https://www.ncbi.nlm.nih.gov/pubmed/36235036
http://dx.doi.org/10.3390/molecules27196500

Ejemplares similares